GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (FRA:9EP) » Definitions » 5-Year Dividend Growth Rate

Enanta Pharmaceuticals (FRA:9EP) 5-Year Dividend Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals 5-Year Dividend Growth Rate?

Enanta Pharmaceuticals's Dividends per Share for the three months ended in Dec. 2024 was €0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Enanta Pharmaceuticals's Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Enanta Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Enanta Pharmaceuticals's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, Enanta Pharmaceuticals's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's 5-Year Dividend Growth Rate falls into.


;
;

Enanta Pharmaceuticals 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Enanta Pharmaceuticals  (FRA:9EP) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Enanta Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2024 )/ EPS without NRI (Q: Dec. 2024 )
=0/ -1.003
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enanta Pharmaceuticals 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Enanta Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals Headlines

No Headlines